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Abstract The forkhead-associated (FHA) domain is a small
protein module recently shown to recognize phosphothreonine
epitopes on proteins. It is present in a diverse range of proteins in
eukaryotic cells, such as kinases, phosphatases, kinesins,
transcription factors, RNA-binding proteins, and metabolic
enzymes. It is also found in a number of bacterial proteins. This
suggests that FHA domain-mediated phospho-dependent assem-
bly of protein complexes is an ancient and widespread regulatory
mechanism. ß 2002 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Modular phosphopeptide recognition is a central compo-
nent of metazoan signal transduction and, until recently,
was generally considered to have evolved in parallel with
metazoan evolution. Indeed, as organisms became more com-
plex, a sophisticated apparatus needed to be developed to
coordinate organismal physiology and development. This sig-
naling apparatus had to be plastic in order to be evolvable
and adaptable and also needed to have a high degree of
speci¢city such that the cell could integrate and compute
environmental cues without confusion. Protein modules pro-
vided part of the solution to this problem and the discovery of
SH2 and SH3 domains initiated an important paradigm shift
in the signaling ¢eld [1].
Signaling protein modules are small independently folded
units having a variety of functions usually centered around
being protein- or ligand-binding domains [1,2]. An important
class of signaling modules is those able to recognize phosphor-
ylated epitopes on proteins. This class of signaling modules
comprises the SH2, PTB and WW domains, 14-3-3 proteins,
and the subject of this review, the forkhead-associated (FHA)
domain [3]. The structural characteristics of protein modules
enable them to be shu¥ed around the genome, providing a
powerful means for the rapid, in evolutionary terms, assembly
of new multi-domain proteins with novel functions [1,2]. As
well as creating new functionalities, the assembly of multi-
domain proteins facilitates the connection of signaling path-
ways and the assembly of highly speci¢c signaling complexes.
This issue of FEBS Letters contains many striking examples
of the use of protein modules in signal transduction. However,
given their great functional versatility, it is not surprising that
protein modules are also used in processes other than signal
transduction. For instance, the modular nature of transcrip-
tional regulators has long been recognized and modular phos-
phopeptide recognition by the FHA domain is associated with
many such processes. In this review, we will describe the re-
cent work that has identi¢ed the FHA domain as a phospho-
peptide-binding module and will summerize some of the var-
ious roles that the FHA domain plays, from bacteria to
humans.
2. The FHA domain: a phosphopeptide-binding module
The FHA domain, discovered in 1995 by Hofmann and
Bucher [4], has recently been shown to be a modular phos-
phopeptide recognition domain with a striking speci¢city for
phosphothreonine (pT)-containing epitopes [5^11]. So far, the
FHA domain has been found in more than 200 di¡erent pro-
teins (cf. http://smart.embl-heidelberg.de/) in species ranging
from prokaryotes to higher eukaryotes, and it is associated
with proteins involved in numerous processes including intra-
cellular signal transduction, transcription, protein transport,
DNA repair and protein degradation [8,11], some of which
are schematically depicted in Fig. 1.
The ¢rst indications of FHA domain involvement in phos-
pho-dependent protein:protein interactions emerged from
studies on two very di¡erent systems: plant signal transduc-
tion and checkpoint signaling [12,13]. In the ¢rst case, a
search for proteins interacting with receptor-like protein ki-
nase RLK5 led Walker and colleagues to the cloning of the
kinase-associated protein phosphatase (KAPP) in 1994 [12].
Importantly, the interaction between KAPP and RLK5 was
found to be dependent on phosphorylation and the region of
KAPP required for this interaction was termed the kinase-
interaction (KI) domain [12]. Four years later, genetic studies
in Arabidopsis indicated that KAPP is a negative regulator of
CLAVATA 1 (CLV1)-dependent signaling [14]. As with the
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KAPP^RLK5 interaction, it was found that KAPP bound
directly to activated CLV1, a plant receptor-like kinase [14].
These genetic and physical interactions suggest that recruit-
ment of KAPP by activated receptors during plant signal
transduction is very similar to the recruitment of SH2-con-
taining tyrosine phosphatases to activated receptor tyrosine
kinases [15], and that phosphorylation-dependent attenuation
of receptor-mediated signaling is a common feature of both
plant and animal cells.
These studies preceded the discovery of the FHA domain,
but in a follow-up study, Walker and colleagues demonstrated
that residues conserved in KAPP’s FHA domains were critical
for KI domain activity [7]. This suggested that the FHA do-
main of KAPP mediates phospho-dependent protein:protein
interactions but did not resolve the important issue of whether
these interactions directly involved the recognition of a phos-
phorylated residue or whether they were initiated by a con-
formational change triggered by phosphorylation.
In parallel, similar conclusions were drawn from studies on
the budding yeast DNA damage checkpoint. In response to
DNA damage, a protein kinase cascade that controls both the
inhibition of cell cycle progression and the DNA repair pro-
cess itself is initiated. In Saccharomyces cerevisiae, this cascade
is, in large part, controlled by the Rad53 protein kinase [16].
Rad53, which contains two FHA domains £anking a central
catalytic protein kinase domain, is a member of a family of
closely related FHA domain-containing protein kinases, other
members of which include the human orthologue, the hCHK2
tumor-suppressor [17], and its S. cerevisiae paralogues, the mei-
otic checkpoint kinases Mek1/Mre4 [4,18] and Dun1 [19,20].
The presence of FHA domains on Rad53 was highly sug-
gestive of a role in protein:protein interactions and, consistent
with this, Rad53 was found to interact with Rad9 following
DNA damage [13,21,22]. The interaction between Rad9 and
Rad53 is dependent on Rad9 phosphorylation [5,13] and was
shown to require at least the C-terminal FHA domain
(FHA2) of Rad53 [13], although the N-terminal FHA domain
(FHA1) is likely to also play an important role in binding [5].
The ¢rst de¢nite demonstration that FHA domains recog-
nize directly phosphorylated instead of epitopes whose un-
masking is triggered by phosphorylation entailed the identi¢-
cation of peptides able to compete the interaction between the
FHA1 domain of Rad53 (Rad53FHA1) and the phosphorylated
forms of Rad9 that occur after DNA damage [5]. A pT-con-
taining peptide derived from the N-terminus of p53, but not
its unphosphorylated counterpart, was found to abrogate the
Rad53FHA1^Rad9 interaction [5]. This pT-containing peptide
was further shown to directly bind Rad53FHA1 and mutation
Fig. 1. The FHA domain is associated with proteins of diverse function. FHA-containing proteins Rad53 (gi: 6325104), KIF1BL (gi : 4512330),
Yhr115c (gi: 6321907), Nbs1 (gi: 14751716), KAPP (gi: 1076344), EspA (gi: 5713126) and Fkh2 (gi: 6324261) are schematically represented
along with their domain organizations. For more information on the domains, please refer to pfam at http://www.sanger.ac.uk/software/pfam/).
The schematized domains are (pfam accession number in brackets): FHA domain (PF00498), BRCA1 C-terminus domain (BRCT; PF00533),
kinesin motor domain (PF00225), PH domain (PF00169), protein kinase domain (kinase, PF00069), protein phosphatase type 2C domain
(PP2C; PF00481), ring-¢nger domain (Ring; PF00097). PAS domain (PF00989), PAC motif (PF00785) and the histidine kinase domain (com-
prising pfam motifs PF00512, PF02518 and PF00072).
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of the conserved Arg70 and His88 residues, but not the var-
iable Asp117 residue, in Rad53FHA1 abolished its interaction
with both the synthetic phosphopeptide and with phosphory-
lated Rad9. Furthermore, the Rad53FHA1 domain was shown
to protect the phosphorylated residue from phosphatase treat-
ment, suggesting that the phosphate moiety is in intimate
contact with the FHA domain [5].
Perhaps surprisingly, this study also demonstrated that the
phosphopeptide^Rad53FHA1 interaction does not take place
when the pT residue is substituted with phosphoserine (pS)
or the acidic amino acid, Asp [5]. However, the phosphopep-
tide^Rad53FHA1 interaction tolerated substitution of the resi-
due at positions pT33 to pT31 (see Fig. 2B) or pT+1 to
pT+2 but did not tolerate substitution of the Asp residue at
pT+3. This latter result indicated that pT+3 is critical for
binding and may be involved in binding selectivity. Impor-
tantly, by examining the ability of many other FHA domains
to bind, in a phospho-dependent manner, to a pT-containing
Fig. 2. FHA domain homology and structure. A: Modi¢ed sequence alignment of the core FHA homology region of various FHA domains
from Rad53 (gi: 6325104), KIF1BL (gi : 4512330), Yhr115c (gi: 6321907), Nbs1 (gi: 14751716), KAPP (gi: 1076344), Chk2 (gi: 6005850), Dun1
(gi: 6320102) and Xrs2 (gi: 2133087). The alignment is based on structural and biochemical data and is based on a similar alignment published
in [6]. The secondary structure ^ in green above the alignment, arrows represent L-sheets ^ is based on the Rad53 FHA domain structures
[6,9]. Conserved residues are bolded and residue Pro578 of KIF1BL is in blue and underlined. B: Ribbons representation of the Rad53FHA1 do-
main in complex with a pT-containing peptide (shown in a ball-and-stick model). The core FHA homology (sheets L3^L10) is colored in green.
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library by surface plasmon resonance, it was concluded that
phospho-dependent binding is a common feature of the FHA
domain [5]. However, the observation that only Rad53FHA1
could bind to a phosphopeptide containing an Asp residue at
pT+3 suggested that FHA domains are likely to recognize
di¡erent sets of phosphopeptide sequences and that selectivity
might be dictated primarily by the pT+3 residue. This hypoth-
esis was con¢rmed in later studies where anchored peptide
libraries were screened against a variety of FHA domains
and consensus binding sequences were thus identi¢ed [6,10].
3. The FHA domain: structure and function
The recent solution of three FHA domain-phosphopeptide
structures by X-ray crystallography and nuclear magnetic res-
onance (NMR) has shed important light on the mechanisms
by which FHA domains recognize phosphorylated epitopes.
The FHA domain itself, as de¢ned by the minimal autono-
mously folded unit, is signi¢cantly larger than the previously
described FHA homology region [6,9,23^25]. It spans approx-
imately 80^100 amino acid residues folded into an 11-stranded
L sandwich, which sometimes contains small helical insertions
between the loops connecting the strands (e.g. between L2 and
L3 in Rad53FHA1 and between L4 and L5 in Chk2FHA ; Fig. 2B
and [6,9,24]). The FHA homology region spans only eight
L-strands on one face of the sandwich (strands L3^L10, Fig. 2)
[6]. Interestingly, the fold of the FHA domain is not unique and
is highly similar to the fold of the Smad MH2 domain [6,9]. The
signi¢cance of this homology is discussed later.
In both the Rad53FHA1 and the Chk2FHA structures, the
phosphopeptide is bound by the loops connecting the L3/L4,
L4/L5 and L6/L7 strands of the FHA domain in an extended
conformation highly reminiscent of the binding of antigen
epitopes on the complementary determining region of anti-
bodies [6]. The determinants of phosphopeptide recognition
by the FHA domain are all embedded in the FHA homology
region and many of the most conserved residues among the
FHA domains play a role in the direct binding of the phos-
phopeptide, either by contacting the phosphopeptide back-
bone (Asn107, Arg70 in Rad53FHA1) or via the pT residue
through an extensive network of hydrogen bonds (Arg70,
Ser85 in Rad53FHA1). In the structures determined to date,
the phosphate moiety of the pT residue does not make salt
bridges with any FHA domain residue and the very conserved
and functionally essential Arg residue (Arg70 in Rad53FHA1
and Arg117 in Chk2) only makes an hydrogen bond with the
Q-oxygen of pT [3,24,26]. This mechanism of recognition of
the pT residue is strikingly di¡erent to that by which pS or
phosphotyrosine (pY) residues are recognized by 14-3-3 pro-
teins, SH2 and PTB domains. In these latter cases, the inter-
action with the phosphorylated residue is stabilized by at least
one Arg residue making a salt bridge with the phosphate
moiety [3,26]. Lastly, two other strongly conserved residues
(Gly69 and His88 in Rad53FHA1, Fig. 2B) stabilize the archi-
tecture of the binding site [6]. We note that these residues have
often been substituted in studies looking at FHA domain
function and we urge caution in using such substitutions in
the future as they may result in the disruption of FHA do-
main tertiary structure. Indeed, mutation of His88 renders
Rad53 unstable in vivo (D.D. and S.P.J., unpublished).
Taken together with the available biochemical data, the
striking conservation of the amino acid residues involved in
phosphopeptide binding, indicated in the structural studies of
FHA domains, strongly suggests that all FHA domains bind
to phosphopeptides [5,6]. The structures also help to ration-
alize the molecular basis of phosphopeptide sequence selectiv-
ity by FHA domains. As discussed above, FHA domains gen-
erally show strong selection for residues at the pT+3 position.
Thus, Rad53FHA1 selects strongly for Asp, whereas Chk2 se-
lects for Ile. Both bind their optimal target phosphopeptides
with similar a⁄nity [5,6,10,24]. By comparing the structures of
the Chk2FHA domain and the Rad53FHA1 domain in a com-
plex with their targets, it can be seen that the extensive net-
work of conserved contacts between the phosphopeptide and
the FHA domain results in a nearly identical extended peptide
conformation in both cases [24]. Perhaps surprisingly, how-
ever, the region of the FHA domain next to the pT+3 residue
is structurally very variable. In the Rad53FHA1 structure, the
pT+3 residue (Asp) makes a salt bridge with the guanidium
moiety of Arg83, which is located in the loop between L4 and
L5 [24]. However, Chk2FHA has an eight-amino acid residue
helical insertion in the L4/L5 loop which results in a structural
conformation radically di¡erent to that of Rad53FHA1. As a
consequence of this insertion, the L4/L5 loop is steered away
from the pT+3 residue, and thus, the pT+3 residue (Ile) is
closely apposed to a region composed of residues from the
L10/L11 loop. Thus, the large variations observed in the
length and composition of both the L4/L5 and L10/L11 loops
among di¡erent FHA domains may explain the diversity in
binding selectivity and rationalize the observation that the
phosphopeptide amino acid residue pT+3 appears to be the
major determinant for binding selectivity [24].
Another striking feature of the FHA domain is its apparent
speci¢city for pT residues over pS residues. Here again, the
crystal structures of the FHA domains of Rad53 (FHA1) and
Chk2 bound to a high-a⁄nity binding pT-containing peptide
illustrate how this speci¢city is imparted. In both structures,
the pT Q-methyl group makes clear side chain interactions
with a conserved Asn residue (Asn107 for Rad53FHA1 and
Asn166 for ChkFHA1) and main chain contacts with a number
of residues (Ser82^Ile84 for Rad53FHA1 and Thr138^Tyr139
for ChkFHA1) [3,6,24,26]. These contacts are thought to largely
explain the speci¢city for pT over pS but experimental con-
¢rmation of this explanation is still required.
Another intriguing feature of the FHA domain is its ability
to bind to peptides containing a pY [27]. It is not clear what
the biological signi¢cance of this ¢nding is, especially in or-
ganisms such as budding yeast where there is a paucity of
tyrosine kinases, but the relatively high binding a⁄nity of a
pY-containing peptide for the FHA2 domain of Rad53 [27]
warrants further examination and suggests that FHA domains
may even recognize other types of phosphoamino acids such
as phosphoaspartate or phosphohistidine.
4. Eukaryotic FHA-containing proteins
Although the FHA domains of several eukaryotic proteins
are now being analyzed, this area of investigation is far from
having reached maturity and the data available amount to
little more than a collection of interacting proteins. Neverthe-
less, the presence of an FHA domain has a predictive value,
i.e. it strongly indicates that the FHA-containing protein will
interact with a protein partner in a process regulated by re-
versible protein phosphorylation. It is therefore not surprising
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that FHA domains are now being used as a tool to decipher
the molecular circuitry of cellular pathways. Below, we review
some of the cellular pathways where FHA-containing proteins
have been identi¢ed to play a role and discuss the potential
signi¢cance of the presence of the FHA domains in these
events.
4.1. DNA damage repair and signaling
The process by which DNA damage is recognized and then
signaled to the cell cycle and DNA repair machineries can be
considered as a bona ¢de signal transduction cascade [28]. It is
initiated by a signal (DNA damage) which is detected by a
receptor or sensor, the precise nature of which remains elusive
to date, and which triggers activation of a proximal set of
kinases (ATM and ATR in mammals; Tel1 and Mec1 in
budding yeast [29,30]). These kinases, in turn, activate a series
of more distal kinases, such as budding yeast Rad53, Dun1
and Chk1, which then phosphorylate and regulate a number
of protein e¡ectors of the checkpoint and DNA damage re-
sponses [16].
FHA-dependent peptide recognition plays a critical role at
many levels in this cascade. In budding yeast, FHA domains
are present on the checkpoint kinases Rad53 and Dun1, and
on Xrs2, the orthologue of Nbs1, the protein encoded by the
gene mutated in the Nijmegen-breakage syndrome (see be-
low). In these three proteins, the FHA domains seem to
play a critical role in integrating upstream signals ([13,20]
and our unpublished results), but most of their cellular part-
ners remain to be identi¢ed.
In humans, the orthologs of RAD53 (CHK2) and XRS2
(NBS1) play a conserved role in the DNA damage checkpoint
response. Chk2 is required to stabilize p53 in response to
DNA damage by phosphorylating it on Ser20 [31^33], where-
as Nbs1 is part of the hMre11/hRad50/Nbs1 (MRN) complex
which plays a pleiotropic role during the S-phase checkpoint
and in DNA repair [34^36]. Mutations in both of these genes
have been associated with an increased cancer risk. Germline
mutations in the CHK2 gene lead to a variant form of the
cancer syndrome Li-Fraumeni [17] and germline mutations in
the NBS1 gene lead to the cancer-prone developmental disor-
der Nijmegen-breakage syndrome [34,35,37]. The FHA do-
mains of both proteins seem to play an important role in
preventing tumorigenesis. In the case of Chk2, two tumor-
associated missense mutations map to the FHA domain,
Ile157Thr and Arg145Trp [17]. Functional and structural
analyses of these mutations have revealed that R145W desta-
bilizes the structure of the FHA domain with an apparent
concomitant reduction in protein stability [24,38,39]. As a
result, this mutated Chk2 is unable to engage in phosphory-
lation-dependent protein:protein interactions and in the
HCT15 cell line, which carries this allele of CHK2, DNA
synthesis continues unchecked after ionizing radiation. This
phenomenon is called radio-resistant DNA synthesis (RDS)
and is a hallmark of a profound S-phase checkpoint defect
[39]. By contrast, the functional outcome of the I157T muta-
tion is more subtle. Despite being unable to complement the
RDS phenotype of the HCT15 tumor cell line [39], Chk2-
I157T is able to bind to phosphorylated epitopes and its ki-
nase activity is still activated after DNA damage [24]. How-
ever, the I157T mutation has the intriguing consequence of
abrogating Chk2 binding to a series of proteins including
Cdc25C, p53 and Brca1, all of which are bona ¢de substrates
for Chk2 kinase activity [24,39,40]. We therefore propose that
the I157T mutation is located in an additional protein inter-
action interface of the FHA domain, which may act as a
substrate docking domain for Chk2 substrates. It will be in-
teresting to test if trans-phosphorylation of biologically rele-
vant substrates is dependent on the integrity of this residue
and to solve, if possible, the structure of the Chk2 kinase
domain in relation to the FHA domain. The absence of e¡ect
on the phosphopeptide-binding ability of the Chk2-I157T mu-
tant is explained by the location of Ile157, which is at the
C-terminal end of the L5/L6 loop of the FHA domain, some
25 Aî away from the phosphopeptide-binding region. Interest-
ingly, the residue, which is largely solvent exposed, lies in an
area corresponding to the SARA (Smad anchor for receptor
activation)-binding interface on the MH2 domain of Smad
[24]. This additional link between the FHA and MH2 do-
mains is compelling and suggests that some FHA^protein
interactions have a binding component that is not phosphor-
ylation-dependent.
Cells from individuals su¡ering from Nijmegen-breakage
syndrome also display a defect in the S-phase checkpoint.
This role of Nbs1 and its orthologues has clearly been con-
served throughout eukaryotic evolution (see above and
[36,41^43]). NBS cells are usually homozygous for a frame-
shift mutation in the NBS1 gene, that results in a premature
termination codon C-terminal to the FHA and BRCT do-
mains [34,35,37]. Conventional wisdom would predict that
the nature of the defect in NBS cells is due to the loss of
the C-terminus of the protein. However, in a recent study,
Maser and colleagues [44] elegantly demonstrated that, in cells
from some NBS patients, an alternative mode of translation
dependent on a cryptic internal ribosome entry site results in
the production of an N-terminally truncated variant of the
Nbs1 protein (p70Nbs1) in addition to the expected C-termi-
nally truncated variant (p26Nbs1) [44]. Furthermore, it was
found that p70Nbs1 could associate with Rad50 and Mre11
whereas p26Nbs1 could not [44]. Satisfyingly, this study recon-
ciles the existence of people with Nijmegen-breakage syn-
drome with the observation that deletion of the NBS1 gene
leads to early embryonic lethality [45] ^ just like the deletion
of hRAD50 [46] ^ and suggests that the essential function of
NBS1 is embedded in the C-terminal region. Thus, the defect
observed in NBS cells might be the consequence of the dis-
sociation of the N-terminus of Nbs1 from the MRN complex.
As the only recognizable motifs in this segment are an FHA
and a BRCT domain, it is therefore likely that loss of either
or both domains from the MRN complex could explain the
aetiology of the disease.
At a cellular level, the MRN complex strikingly localizes to
sites of DNA strand-breaks after irradiation in a manner that
is dependent on checkpoint kinase activity [47,48]. This relo-
cation to sites of DNA damage is lost in NBS cells and a
recent report supports the hypothesis that the Nbs1 FHA
domain is necessary for this process [49]. However, in this
latter study, the Nbs1 mutant used to ascribe a role to the
FHA domain in MRN complex relocation was a deletion of
the whole FHA domain, and therefore, one cannot exclude
the possibility that the deletion may have altered the Nbs1
structure or conformation. A mouse mutant speci¢cally mu-
tated within the FHA domain of Nbs1 may resolve the role of
this domain in the cellular pathology of the Nijmegen-break-
age syndrome as well as the potential role of the FHA domain
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in mediating MRN complex recruitment to sites of DNA
damage. Needless to say, it will be fascinating to identify
proteins that interact with the FHA domain of Nbs1 and to
understand their role in the various functions of the MRN
complex.
4.2. Kinesins
The kinesin superfamily is the largest family of FHA-con-
taining proteins in eukaryotes. More than 20 di¡erent kinesin-
like proteins present in species from worms to humans contain
FHA domains. This subset of kinesin-like proteins is part of
the N3 class of kinesins [50]. FHA-containing members of this
class comprise kinesins of the UNC104 family (KIF1A,
KIF1B, KIF1C and its orthologs such as Caenorhabditis ele-
gans orthologue unc-104) and kinesins of the KIF14 family
(including KIAA0042 and its orthologue from Drosophila
melanogaster, KLP38b/nebbish/tiovivo) [51]. These kinesins
are involved in vesicular transport (e.g. KIF1A/unc-104 and
KIF1BL ; [51^55]) or, in the case of KLP38b, in chromosome
segregation [56^58]. Interestingly, a mutation in the gene en-
coding the KIF1BL protein is responsible for the Charcot-
Marie-Tooth disease type 2A, indicating that FHA-containing
kinesins may have a role in the development of human neuro-
pathies [55].
Recent biophysical measurements have established that the
kinesin FHA domain is an independently folded structural
unit with a topology likely to be identical to that of the
FHA domains of known structures [25]. Interestingly, the
structure of the kinesin motor domain of KIF1A has been
solved in both its ATP- and ADP-bound forms. The FHA
domain is located close to the active site of the kinesin and
this has led to the proposition that the FHA domain might
play a role in regulating the catalytic cycle by binding to
tubulin, the substrate of the kinesin [59]. Another equally
interesting possibility is that the FHA domain is a site of
phosphorylation-dependent cargo docking. As C. elegans
UNC-104 and its mammalian counterpart, KIF1A/ATSV,
transport synaptic vesicles, it is probable that the uptake of
mature vesicles by kinesins is a regulated process. In any case,
it will be exciting to test whether the transport process is
regulated by FHA-mediated phospho-dependent interactions,
whether it be via binding to tubulins, cargo proteins or other
regulators.
Although no FHA-interacting proteins have yet been iden-
ti¢ed that interact with UNC-104-type family kinesins, a re-
cent report suggests that the FHA domain of mouse KIF1C is
functionally important [60]. In this study, mutation of the Pro
residue at position 578 to Leu in the FHA domain of murine
KIF1C is closely linked to resistance to anthrax lethal factor.
Homology mapping of this residue on the available structures
(Fig. 2A) suggests that Pro578 might play a role in the turn
occurring in the L8/L9 loop and that substitution of Pro578 to
Leu might result in a signi¢cantly altered FHA domain. It will
be interesting to examine whether this mutation alters KIF1C
motility or whether it a¡ects the transport of a yet-to-be iden-
ti¢ed cargo.
4.3. Ring-¢nger proteins containing FHA domains: a role in
protein degradation?
Ring-¢nger-containing FHA domains account for another
class of FHA-containing proteins that is conserved from yeast
to man. Two members of this family have been characterized
so far: Schizosaccharomyces pombe dma1 and human Chfr.
Fission yeast dma1 has been identi¢ed as a multi-copy sup-
pressor of a cdc16 mutation, which encodes the S. pombe
homolog of the budding yeast BUB2 spindle checkpoint/mi-
totic exit regulator [61]. Deletion of dma1 leads to sensitivity
to microtubule-destabilizing agents, suggesting that, like
BUB2, it may play a direct role in the spindle checkpoint
pathway or the ¢ssion yeast equivalent of the mitotic exit
pathway, the septation initiation network [61].
Exciting work from the Halazonetis laboratory has lead to
the identi¢cation of Chfr as a protein required for a novel
checkpoint that regulates the integrity of centrosome separa-
tion and prevents entry into metaphase in the presence of
mitotic stress [62]. Interestingly, Chfr expression is undetect-
able in some cancer cells and the CHFR gene carries missense
mutations in others, suggesting that inactivation of CHFR
might play a role in cancer progression [62]. Studies on pri-
mary tumors and matched controls are required to de¢nitely
ascribe a role for Chfr in carcinogenesis [63]. Nevertheless, we
know that the FHA domain of Chfr is required for its pro-
phase checkpoint activity, as deletion of the FHA domain
results in a dominant-negative protein that is unable to re-
strain metaphase entry in response to mitotic stress [62].
The presence of the ring-¢nger in this family of FHA-con-
taining proteins is highly suggestive of a role in protein ubiq-
uitination and/or degradation since it is the catalytic motif of
a variety E3 ubiquitin ligases [64]. Furthermore, the inclusion
of the FHA domain in these putative E3 ubiquitin ligases
suggests that they will be recruited either to upstream regu-
lators (such as an E2) and/or to potential substrates by phos-
phorylation-dependent protein:protein interactions.
4.4. Forkhead transcription factors
The term ‘forkhead-associated’ domain was originally given
to the domain discussed in this review to underline the pres-
ence of this domain on a small subset of forkhead-type tran-
scription factors [4]. In S. cerevisiae, four members of this
subfamily exist (Fkh1, Fkh2, Flh1 and Flh2) and they form
the largest family of FHA-containing proteins in this organ-
ism. FHA-containing forkhead-type transcription factors can
be found in many eukaryotes; in humans, the MNF and
ILF1/2 transcription factors are of this subfamily. Fkh1 and
Fkh2 were recently found to be master regulators of G2-spe-
ci¢c transcription in budding yeast [65^69]. They are compo-
nents of the Swi5-factor (SFF) and regulate transcription of
the CLB2 and SIC1 cluster [65^68]. The role(s) of the Fkh1
and Fkh2 FHA domains is still unknown, but a possible sig-
nal-dependent association with their cofactors Ndd1 and
Mcm1 is worth investigating. Given the importance of these
genes in budding yeast and the presence of FHA-containing
forkhead-type transcription factors in mammals, it is tempting
to speculate that mammalian counterparts of Fkh1/2 might
play a similar role in regulating some aspects of cell cycle
control.
4.5. Ki-67
Ki-67, a widely used proliferation marker [70], is a rather
large protein containing an FHA domain in its N-terminus,
followed by a large number of repeats reminiscent of PEST
sequences which are involved in protein decay [70,71]. Ki-67
seems to be an essential component of cellular proliferation
since antisense oligonucleotides directed against Ki-67 inhibit
FEBS 25675 21-2-02 Cyaan Magenta Geel Zwart
D. Durocher, S.P. Jackson/FEBS Letters 513 (2002) 58^66 63
cellular proliferation [71]. Its cellular localization is very dy-
namic during the cell cycle. During interphase, Ki-67 is mainly
found associated with the nucleolus [70]. However, during
mitosis, Ki-67 relocalizes to condensed chromosomes, suggest-
ing that it my have a role in chromosome condensation. It will
be interesting to examine whether the FHA domain is in-
volved in the dynamic redistribution of Ki-67 at mitosis.
In an attempt to understand the function of the FHA do-
main of Ki-67, a yeast two-hybrid screen was undertaken by
the group of Yoneda and colleagues. Ten positive clones rep-
resenting two cDNAs were obtained, identifying the kinesin-
like protein Hklp2 and a putative nucleolar RNA-binding
protein, NIFK1, as speci¢c interactors with the FHA domain
of Ki-67 [72,73]. Both proteins are able to interact with a
recombinant GST^FHA(Ki-67) domain fusion protein in a
phospho-dependent manner, and both seem to partially over-
lap with Ki-67 in terms of cellular localization. However, the
functional signi¢cance of these interactions remain to be dem-
onstrated. Interestingly, after phosphorylation with cyclin-cdk
kinases, recombinant portions of NIFK1 and Hklp2 were able
to interact with recombinant FHA domain of Ki-67 [72,73].
Mapping of the NIFK1 and Hklp2 sites responsible for this
interaction revealed that they contained a Thr^Pro consensus
motif. This result suggests that the Ki-67 FHA domain may
form a new subclass of FHA domains specialized in recogniz-
ing mitotic phosphoproteins via a pT^proline motif.
4.6. Nuclear inhibitor of protein phosphatase 1 (NIPP-1)
The NIPP-1 is a metazoan regulator of type 1 protein phos-
phatases (PP1). PP1 dephosphorylates Ser/Thr residues on a
variety of proteins and the timely regulation of these dephos-
phorylation events is thought to be controlled by the associ-
ation of PP1 with small regulatory subunits such as NIPP-1
[74,75]. The subcellular localization of NIPP-1 is striking
being mainly in nuclear speckles, which are sites of splicing
or storage of splicing factors [74,75]. It has therefore been
proposed that NIPP-1 speci¢cally targets PP1 to the splicing
apparatus and that PP1 acts as a regulator of pre-mRNA
splicing. Interestingly, mapping studies have revealed that
the FHA domain of NIPP1 is required for the subnuclear
localization of NIPP1 to the spliceosomal compartment [76],
suggesting that the NIPP-1 FHA domain might have a target-
ing function.
Based on the conservation of the FHA domain among
NIPP-1 orthologues and its newly identi¢ed role as a phos-
phopeptide-binding domain, Boudrez et al. [77] used the FHA
domain of NIPP-1 as a bait in a yeast two-hybrid screen and
identi¢ed the human homolog of S. pombe cdc5, CDC5L, as
a speci¢c interactor. The interaction is phospho-speci¢c and
cdk2/cyclin E can promote the CDC5L^NIPP-1 interaction in
vitro. Mounting evidence supports a role in pre-mRNA splic-
ing for CDC5L and its orthologues and, despite the absence
of a perfect colocalization of NIPP1 with CDC5L, this inter-
action may be of physiological relevance, especially given the
suspected role of the FHA domain of NIPP1 in regulating its
subnuclear targeting [76].
5. A bacterial origin for the FHA domain: speculation and
implications
A large number of prokaryotic genomes have been or are
being fully sequenced. This endeavor has revealed a previously
unsuspected but widespread presence of FHA-containing pro-
teins in eubacteria but not, so far, in archaea. Although there
is a lack of functional data on most of these proteins, the
information we have suggests that FHA domains are most
common in organisms having complex life cycles such as
Myxococcus xanthus or in pathogenic bacteria such as myco-
bacteria. For example, in M. xanthus, the espA histidine ki-
nase, which contains an FHA domain, is involved in the
highly regulated process of sporulation [78].
The presence of genes encoding FHA-containing proteins in
eubacterial and eukaryotic genomes, but not in archaeal ge-
nomes, is intriguing. It strongly suggests that lateral gene
transfer has occurred to enable one kingdom to obtain the
FHA domain from the other. However, if transfers have oc-
curred, the directionality of the transfer remains unclear. For
intracellular parasites, some of the ¢rst prokaryotes to be
sequenced, the presence of putative FHA-containing proteins
might be the result of these organisms capturing genes encod-
ing FHA-containing proteins from their eukaryotic hosts.
However, FHA-containing proteins are also found in a wide
variety of bacterial species, some of them being free-living,
such as M. xanthus, Deinococcus radiodurans, Anabaena, Ba-
cillus halodurans, Synechocystis, Streptomyces coelicolor, Pseu-
domonas aeruginosa, and Agrobacterium tumefaciens (cf.
http://smart.embl-heidelberg.de/). These are representatives
of both Gram-positive and Gram-negative bacteria are found
in diverse ecosystems, and the presence of FHA domains in
proteobacteria [79] (the proposed ancestors of the mitochon-
drion) and cyanobacteria [80] (the ancestors of chloroplasts)
raises the possibility that eukaryotic FHA domains have
evolved from nuclear-transferred genes from endosymbionts.
It is also worth noting that in plants such as Arabidopsis
thaliana, the FHA domain-containing enzyme zeaxanthin ep-
oxidase, which is a key enzyme in the production of the com-
mercially important plant hormone abscisic acid, is localized
in the chloroplast [81], further suggesting a possible endosym-
biotic origin for eukaryotic FHA domains.
Whatever the origin of bacterial FHA domains, it remains
intriguing that modular phosphopeptide recognition has
evolved many times during evolution. This may indicate
that some modules have biophysical properties that are best
suited for some biological functions but not for others. For
example, it is not hard to imagine how a phosphopeptide-
binding module on signal transduction proteins may need
properties that are distinct from those present on kinesins.
Since the FHA domain appears to be an ancient module,
one might also ¢nd instances where the FHA domain has
been replaced by or has replaced another phosphopeptide-
binding module during the course of evolution. This may be
the case for the PinA protein of Dictyostelium discoideum
(DdPinA, gi:1688322), a peptidyl-prolyl isomerase of the
Pin1 family. Unlike its other eukaryotic counterparts,
DdPinA does not contain a phosphopeptide-binding WW
domain in its N-terminus, but instead has an FHA domain.
It is not clear whether this represents a case where the FHA
domain has replaced the WW domain, whether the ancestral
Pin1 contained an FHA domain that was subsequently sup-
planted by the WW domain, or whether convergent evolu-
tion has occurred. In any case, it will be interesting to examine
more closely the full extent of the binding selectivity and
biophysical characteristics of the pT^FHA interaction for
a large number of diverse FHA-containing proteins from
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both prokaryotes and eukaryotes in order to glean some an-
swers.
Finally, another implication of the widespread presence of
FHA domains in bacteria is the obligatory corollary that
phosphorylation-dependent assembly of protein complexes in
bacteria should also be a widespread process. It is not yet
clear what kind of phosphorylated amino acid residues bacte-
rial FHA domains recognize in bacteria but it will be fasci-
nating to examine how phosphorylation regulates protein
complex assembly in these organisms.
6. The MH2 domain: a divergent FHA domain?
One of the most intriguing observations arising from the
NMR and crystallography studies of FHA domains is the
striking similarity between in the core L-sheet topology of
the FHA and Smad MH2 domains [6,9]. The MH2 domain
of Smad transcriptional regulators plays a critical role in
Smad-dependent TGFL signaling and acts as a protein:pro-
tein interaction interface [82]. In a recent report, Huse et al.
[83] proposed that the conserved fold might indicate function-
al conservation and that the Smad MH2 domain serves as a
binding interface for the tetraphosphorylated type I TGFL
receptor (TLR-I) [83]. The mapping of the interaction deter-
minants on the MH2 domain revealed that the region required
for the interaction of MH2 with the TLR-I-derived phospho-
peptide coincides with the phosphopeptide interaction region
of FHA domains, i.e. in the loops connecting the L-strands of
the sandwich [83]. This striking similarity leads to the exciting
possibility that the FHA and Smad MH2 domains might
share a common ancestor that possessed phosphopeptide-
binding activity. We await the co-crystallization of the MH2
domain bound to the phosphorylated TLR-I peptide, which
should shed important light on how this conserved structure
binds to multiply phosphorylated peptides.
7. Conclusion
The widespread structural spectrum of phosphopeptide rec-
ognition modules suggests that this strategy has been discov-
ered multiple times during evolution, providing a testament to
the selective advantage a¡orded by the strategy. Many major
challenges remain for those of us interested in FHA domain
function, including questions about the function of the FHA
domain in the major classes of FHA-containing proteins, the
role of FHA domains in prokaryotes, the exciting relation
between FHA and Smad MH2 domains, and the molecular
and structural determinants of ligand selectivity. We also note
that, with the recent progress in developing e⁄cacious anti-
SH2 compounds [84], there is an obvious interest in identify-
ing similar anti-FHA molecules that could block signal-depen-
dent protein:protein interactions. These could prove to be of
therapeutic value in a variety of contexts and might also pro-
vide valuable tools to probe FHA-dependent processes in
vivo.
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